Overview
Alternative Name Mu-Conotoxin BuIIIC
Lyophilized Powder yes
Origin Synthetic peptide
MW: 3006 Da
Purity: >98% (HPLC)
Form Lyophilized powder.
Effective concentration 1 pM - 20 nM.
Sequence IVDRCCNKGNGKRGCSRWCRDHSRCC.
Modifications Disulfide bonds between Cys5-Cys19, Cys6-Cys25, and Cys15-Cys26. Cys26 - C-terminal amidation.
Structure
Molecular formula C116H189N49O34S6.
Activity µ-Conotoxin BuIIIC is a selective NaV1.4 blocker1.
References-Activity
- Holford, M. et al. (2009) Toxicon 53, 90.
Accession number C1J5M7.
Shipping and storage Shipped at room temperature. Product as supplied can be stored intact at room temperature for several weeks. For longer periods, it should be stored at -20°C.
Solubility Any other aqueous buffer. Centrifuge all product preparations before use (10000 x g 5 min).
Storage of solutions Up to two weeks at 4°C or three months at -20°C.
Our bioassay
Alomone Labs µ-Conotoxin BuIIIC blocks NaV1.4 currents expressed in Xenopus oocytes.A. Time course of µ-Conotoxin BuIIIC (#STC-690) blocking action on NaV1.4 currents. Peak current amplitude was plotted as a function of time. Membrane potential was held at -100 mV and cells were stimulated by a 100 ms voltage step to -10 mV. 20 nM µ-Conotoxin BuIIIC were perfused as indicated by the bar (green) during 5 min. B. Superimposed examples of NaV1.4 channel current in the absence (control) and presence (green) of 20 nM µ-Conotoxin BuIIIC (taken from the experiment in A).
Scientific background μ-conotoxin BuIIIC, is a peptide toxin originally isolated from Conus Bullatus (Bubble cone). It has the characteristic arrangement of six-cysteine residues (-CC-C-C-CC-) and comprises 26 amino acid residues. μ-conotoxin BuIIIC was demonstrated to be a potent irreversible inhibitor of the voltage-gated Na+ channel skeletal muscle subtype NaV1.4, expressed in Xenopus oocytes. 1 μM toxin was shown to block 96% of the channel. The novel structural determinants of BuIIIC along with its ability to potently inhibit NaV1.4 make this conotoxin useful in defining features of the NaV1.4 pharmacophore and thereby facilitate the design of highly subtype-specific ligands that target NaV1.41.
Target NaV1.4 Na+ channels
Peptide Content: 100%
Lyophilized Powder
For research purposes only, not for human use
Last Update: 07/05/2024
Specifications
Citations
Citations
